Cargando…

Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer

AIM: We previously developed two antibodies that bind to a cell surface protein, perlecan, overexpressed in triple-negative breast cancer (TNBC). The goal of this study was to investigate these antibodies as targeting ligands for nanoparticle-mediated drug delivery. METHODS: Paclitaxel-loaded poly(D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khanna, Vidhi, Kalscheuer, Stephen, Kirtane, Ameya, Zhang, Wenqiu, Panyam, Jayanth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Newlands Press Ltd 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700713/ https://www.ncbi.nlm.nih.gov/pubmed/31448368 http://dx.doi.org/10.4155/fdd-2019-0005

Ejemplares similares

Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer
por: Kalscheuer, Stephen, et al.
Publicado: (2019)

Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
por: Khanna, Vidhi, et al.
Publicado: (2021)

Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index
por: Kirtane, Ameya R., et al.
Publicado: (2015)

Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors
por: Song, Jung Min, et al.
Publicado: (2016)

Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling
por: Song, Jung Min, et al.
Publicado: (2017)

Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy
por: Arora, Sumit, et al.
Publicado: (2014)

Silicate Esters of Paclitaxel and Docetaxel: Synthesis, Hydrophobicity, Hydrolytic Stability, Cytotoxicity, and Prodrug Potential
por: Wohl, Adam R., et al.
Publicado: (2014)

Expression of the Heparan Sulfate Proteoglycan, Perlecan, during Mouse Embryogenesis and Perlecan Chondrogenic Activity In Vitro
por: French, M.M., et al.
Publicado: (1999)

RNA nanoparticles for targeted therapies of triple-negative breast cancers
por: Danai, Leyla, et al.
Publicado: (2023)

Perlecan controls neurogenesis in the developing telencephalon
por: Girós, Amparo, et al.
Publicado: (2007)

Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
por: Fang, Hanyi, et al.
Publicado: (2021)

Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment
por: Al-jubori, Ali A., et al.
Publicado: (2021)

Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer
por: Gu, Fenfen, et al.
Publicado: (2022)

Life without Perlecan Has Its Problems
por: Olsen, Bjorn R.
Publicado: (1999)

Perlecan and the Blood-Brain Barrier: Beneficial Proteolysis?
por: Roberts, Jill, et al.
Publicado: (2012)

Perlecan and synaptophysin changes in denervated skeletal muscle☆
por: Ma, Kai, et al.
Publicado: (2012)

Increased Risk of Aortic Dissection with Perlecan Deficiency
por: Nonaka, Risa, et al.
Publicado: (2021)

Similarity of Recombinant Human Perlecan Domain 1 by Alternative Expression Systems Bioactive Heterogenous Recombinant Human Perlecan D1
por: Ellis, April L, et al.
Publicado: (2010)

Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice
por: Zhang, Tian, et al.
Publicado: (2017)

Tumor-Targeted Erythrocyte Membrane Nanoparticles for Theranostics of Triple-Negative Breast Cancer
por: Choi, Moon Jung, et al.
Publicado: (2023)

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
por: Zeng, Weiwei, et al.
Publicado: (2023)

The effects of collagen-rich extracellular matrix on the intracellular delivery of glycol chitosan nanoparticles in human lung fibroblasts
por: Yhee, Ji Young, et al.
Publicado: (2017)

Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy
por: Misra, Ranjita, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

Acetylcholinesterase Clustering at the Neuromuscular Junction Involves Perlecan and Dystroglycan
por: Peng, H. Benjamin, et al.
Publicado: (1999)

Perlecan Maintains the Integrity of Cartilage and Some Basement Membranes
por: Costell, Mercedes, et al.
Publicado: (1999)

Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)

Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner, Jessica, et al.
Publicado: (2015)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
por: Gul, Samina, et al.
Publicado: (2023)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
por: Wang, Zhongjie, et al.
Publicado: (2023)

Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles
por: Moku, Gopikrishna, et al.
Publicado: (2019)

A central function for perlecan in skeletal muscle and cardiovascular development
por: Zoeller, Jason J., et al.
Publicado: (2008)

Perlecan Maintains Microvessel Integrity In Vivo and Modulates Their Formation In Vitro
por: Gustafsson, Erika, et al.
Publicado: (2013)

Perlecan regulates bidirectional Wnt signaling at the Drosophila neuromuscular junction
por: Kamimura, Keisuke, et al.
Publicado: (2013)

Modular Proteoglycan Perlecan/HSPG2: Mutations, Phenotypes, and Functions
por: Martinez, Jerahme R., et al.
Publicado: (2018)

Review of Alterations in Perlecan-Associated Vascular Risk Factors in Dementia
por: Trout, Amanda L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pcbkba6842iakngnd24fn1onbf